Compare

KLOW Blend vs Larazotide

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

KLOW Blend

2233 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 24% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
-124
Mood
-50
Focus
-86
Sleep quality
-136
Lean mass
-164

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
-28
Fatigue
-151
Nausea
-121
Water retention
-140
Appetite loss
-165

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–3 mg

0.01–0.025 mg
2
0.025–0.05 mg
10
0.05–0.1 mg
18
0.1–0.2 mg
21
0.2–0.4 mg
26
0.4–0.6 mg
18
0.6–1 mg
10
1–2 mg
7
2–3 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing37stacking25side effects33klow blend16

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 15 days · Based on 491 repeat reporters

Larazotide

1343 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 47% · Mixed 34% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
-14
Mood
-82
Focus
-135
Sleep quality
-142
Lean mass
-143

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
-98
Fatigue
-2
Nausea
10
Water retention
-146
Appetite loss
-143

Self-reported dose per injection

Median bucket: 1–2 mg · Most common: 0.6–1 mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
5
0.2–0.4 mg
15
0.4–0.6 mg
19
0.6–1 mg
29
1–2 mg
24
2–3 mg
13
3–5 mg
9
5+ mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing27stacking10side effects13larazotide26

How repeat users are trending

Among repeat reporters, 57% said they felt similar to their last entry, 45% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 295 repeat reporters

Sources (7)

Published sources linked on the KLOW Blend and Larazotide wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  3. Review Article

    GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes

    Pickart L, Margolina A. Cosmetics. 2018

    Source
    Wiki study page →
  4. PubMed

    Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet

    Leffler DA, Kelly CP, Abdallah HZ, et al. Gastroenterology. 2015

    Source
    Wiki study page →
  5. PubMed

    Coeliac disease and the intestinal barrier: mechanisms of disruption and strategies for restoration

    Damianos JA, Bledsoe A, Camilleri M, et al. Gut. 2026

    Source
    Wiki study page →
  6. PubMed

    The potential utility of tight junction regulation in celiac disease: focus on larazotide acetate

    Khaleghi S, Ju JM, Lamba A, et al. Therapeutic advances in gastroenterology. 2016

    Source
    Wiki study page →